Arch Biopartners Stock Quote ARCH - Stock Price, News, Charts, Message Board, Trades

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.84

Bid

1.84

Ask

1.86

Volume

2,900

1.84 Day's Range 1.88

1.36 52 Week Range 2.56

Market Cap

118.956M

Previous Close

1.82

Open

1.88

Last Trade

100

1.84

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

11,625

Shares Outstanding

64,650,000

Dividend Yield

PE Ratio

-30.53

Earnings Per Share (EPS)

-0.06

Revenue

2.12M

Net Profit

-3.92M

Sector

Coml Physical, Biologcl Resh

Industry

Advertising Agencies

Headquarters

Toronto, Ontario, Can

Founded

2010

Arch Biopartners Inc is listed in the Coml Physical, Biologcl Resh sector of the TSX Venture Exchange with ticker ARCH. The last closing price for Arch Biopartners was $1.82. Over the last year, Arch Biopartners shares have traded in a share price range of $ 1.36 to $ 2.56.

Arch Biopartners currently has 64,650,000 shares outstanding. The market capitalization of Arch Biopartners is $117.66 million. Arch Biopartners has a price to earnings ratio (PE ratio) of -30.53.

Arch Biopartners Arranges Non-Brokered Private Placement

TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Shares for Interest Debt Settlement

TORONTO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Dosing of First Patient in a Trial for LSALT Peptide is Sending Shares HIgher

This late-stage clinical trial company focuses on preventing inflammation and acute organ injury. It is developing a platform of new drugs to...

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

TORONTO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture:...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.09	-4.66321243523	1.93	1.93	1.77	7441	1.86827989	CS
4	-0.02	-1.0752688172	1.86	1.94	1.75	10104	1.88291283	CS
12	-0.08	-4.16666666667	1.92	2.01	1.59	11625	1.87027027	CS
26	0.37	25.1700680272	1.47	2.2	1.45	13297	1.89720324	CS
52	0.28	17.9487179487	1.56	2.56	1.36	18034	1.90255149	CS
156	-1.47	-44.4108761329	3.31	4.25	0.97	19167	2.11118226	CS
260	1	119.047619048	0.84	5.3	0.74	27058	2.00319695	CS

ARCH - Frequently Asked Questions (FAQ)

What is the current Arch Biopartners share price?

The current share price of Arch Biopartners is $ 1.84

How many Arch Biopartners shares are in issue?

Arch Biopartners has 64,650,000 shares in issue

What is the market cap of Arch Biopartners?

The market capitalisation of Arch Biopartners is CAD 117.66M

What is the 1 year trading range for Arch Biopartners share price?

Arch Biopartners has traded in the range of $ 1.36 to $ 2.56 during the past year

What is the PE ratio of Arch Biopartners?

The price to earnings ratio of Arch Biopartners is -30.53

What is the cash to sales ratio of Arch Biopartners?

The cash to sales ratio of Arch Biopartners is 56.4

What is the reporting currency for Arch Biopartners?

Arch Biopartners reports financial results in CAD

What is the latest annual turnover for Arch Biopartners?

The latest annual turnover of Arch Biopartners is CAD 2.12M

What is the latest annual profit for Arch Biopartners?

The latest annual profit of Arch Biopartners is CAD -3.92M

What is the registered address of Arch Biopartners?

The registered address for Arch Biopartners is 545 KING ST W, TORONTO, ONTARIO, M5V 1M1

Which industry sector does Arch Biopartners operate in?

Arch Biopartners operates in the ADVERTISING AGENCIES sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
HHHHelius Minerals Limited	$ 0.28 (154.55%)	293.73k
CZ.HCassius Ventures Ltd	$ 0.15 (114.29%)	20k
AQSAequus Pharmaceuticals Inc	$ 0.01 (100.00%)	149.24k
HCC.HHanna Capital Corp	$ 0.01 (100.00%)	87.81k
GALGalantas Gold Corporation	$ 0.085 (54.55%)	418.43k
ROVRRover Critical Minerals Corp	$ 0.01 (-50.00%)	1k
TEATearlach Resources Limited	$ 0.01 (-50.00%)	71.52k
TVITVI Pacific Inc	$ 0.005 (-50.00%)	5.4k
HTC.HHTC Purenergy Inc	$ 0.005 (-50.00%)	414.1k
ALTAlturas Minerals Corp	$ 0.005 (-50.00%)	1,000
TSGTriStar Gold Inc	$ 0.205 (13.89%)	7.67M
GSVRGuanajuato Silver Company Ltd	$ 0.17 (-2.86%)	2.9M
SLGSan Lorenzo Gold Corp	$ 0.25 (13.64%)	2.39M
FTZFitzroy Minerals Inc	$ 0.195 (14.71%)	1.79M
WRLGWest Red Lake Gold Mines Ltd	$ 0.62 (3.33%)	1.67M